ARCHIVES

Adverse data from cancer prevention trial makes Merck withdraw Vioxx from market. Researchers discuss implications for other cancer prevention trials.

This article is from The Cancer Letter archive.

Vol. 30 No. 39 | October 15, 2004

Download PDF Visit The Full Archive

Related Articles

In Brief: Saunders Retires As Dean of UT Graduate School At Galveston; Started Centers Program At NCI

August 21, 1987

ACCC Members Hear How Community Cancer Programs Are Developed

February 11, 1977

Clinical Trials Approved By NCI

November 26, 2010

After Congressional Inquiry, NCI Posts Ambiguous Statement On Abortion And Breast Cancer Risk

December 13, 2002

Nutrition Program Starts To Zero In On Mass Of Data, Plan Contract And Grant Project Areas

August 29, 1975

Arizona Cancer Center Convinces State To Set Lower Limits For Aflatoxin

February 23, 1979